Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial.

Vaccines (Basel) · 2013 · PMC4494211 · PMID 26344340

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

Several secondary endpoints representative of the clinical manifestations attributed directly or indirectly to CMV infection were numerically lower in the vaccine group compared to the placebo group but did not achieve significance; however, this study was not powered to detect differences in these endpoints.

also in 1,397 other papers

a trend towards significanceno p-value reported

The geometric mean gB antibody levels were not significantly higher in the ASP0113 group than in the placebo group until after the fourth injection, when the gB antibody levels showed a trend towards significance at Day 210 and reached significance by Day 365 ( p = 0.064 and 0.009, respectively; Wilcoxon rank-sum test).

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.